Eomesodermin Expression in Memory T Cells for Rejection Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pre-existing alloreactive memory T cells, particularly those resistant to co-stimulation blockade, pose a significant barrier to the induction of tolerance in organ transplant recipients, leading to allograft rejection.
Innovation Solution
Measuring Eomes expression in memory T cells to predict the risk of allograft rejection and modifying immunosuppressive therapy based on these measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If co-stimulation blockade is used to prevent allograft rejection, then acute cellular rejection is reduced, but pre-existing alloreactive memory T cells remain resistant and cause rejection
Solution Approach 1:
The patent measures Eomes expression in memory T cells before transplantation to identify patients at high risk for rejection. This preliminary assessment allows for pre-transplant counseling and potential modification of immunosuppressive therapy protocols, addressing the resistant memory T cell problem before it can cause rejection.
Solution Approach 2:
The patent establishes a monitoring system that measures Eomes expression in memory T cells after transplantation to assess rejection risk. This feedback mechanism enables dynamic adjustment of immunosuppressive therapy based on the patient's immune response status, improving allograft survival by adapting treatment to the persistent threat of resistant memory T cells.
2Reliability
If immunosuppressive therapy is intensified to prevent rejection by resistant memory T cells, then allograft survival improves, but patient safety and quality of life deteriorate
Solution Approach 1:
The patent uses Eomes expression levels as a specific parameter to stratify patients into different risk categories. By changing the parameter of measurement from generic immune markers to Eomes-specific expression, the system enables personalized immunosuppressive therapy dosing that targets only those patients with high Eomes expression, avoiding unnecessary intensification of therapy for low-risk patients and thereby improving safety while maintaining graft survival.
Solution Approach 2:
The patent applies different immunosuppressive strategies to different patient subgroups based on their Eomes expression levels. High Eomes expression patients receive intensified therapy, while low Eomes expression patients receive standard or reduced therapy. This local differentiation of treatment quality optimizes both graft survival and patient safety by avoiding unnecessary therapy intensity in low-risk patients.
3Adaptability or versatility
If Eomes expression is measured in all transplant patients, then personalized therapy can be implemented, but measurement complexity and cost increase
Solution Approach 1:
The patent replaces complex multi-parameter flow cytometry analyses with a focused measurement system that specifically targets Eomes expression on memory T cells. By substituting the need for comprehensive immune profiling with a specialized Eomes assay, the system achieves personalized therapy capability while reducing measurement complexity and cost through targeted rather than blanket analysis.
Data Source
AI summary
Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.